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1. Introduction 
There is now a plethora of different imaging techniques used for diagnosing and treating 
brain tumours. Different contrast agents in magnetic resonance imaging – coupled with 
amino acid tracers used in positron emission tomography – are the new weapons in 
radiologists’ armoury which allow them to target and measure tumours more accurately. 
Brain tumours are among the top causes of tumour-related deaths, with ten to 15 out of 
every 100,000 people diagnosed in Europe and USA every year.  
The evaluation of tumours with medical imaging modalities is now one of the primary 
concerns of radiology departments. Computed tomography (CT), magnetic resonance 
imaging (MRI) and various advanced MRI techniques like perfusion MRI and dynamic 
susceptibility contrast (DSC) MRI play a vital role in brain tumour assessment.  
In this chapter, we will summarize the current clinical applications of Computed 
Tomography, gadolinium contrast agents in neuro-imaging, including contrast-enhanced 
MRI, perfusion-weighted imaging and positron emission tomography (PET) for evaluation 
of brain tumour lesions. We will also discuss the advantages and limitation of each modality 
with respect to answering the specific clinical concerns. 
2. Role of imaging in brain tumour assessment 
In the management of patients with confirmed / suspected intracranial tumours, imaging of 
brain is often required at various stages and has a significant role at each level. Several 
stages of management may be considered although they are in practice often integrated with 
each other [1].  
i. Detection / confirmation of a structural abnormality 
ii. Localization and assessment of extent of the lesion 
iii.  Characterization – distinction between neoplastic and non-neoplastic lesions, if 
neoplastic then differentiation among  malignant and benign  
iv. Staging of the tumour: lymphatic spread or other organ involvement 
v. Looking for involvement of any vital brain area which might be of concern for therapy 
planning 
vi. Facilitate surgical planning or other therapeutic interventions 
vii. Intraoperative control of resection procedure 
viii.  Monitoring prognosis and follow up 
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CT is often the first line of imaging study in tumour assessment because it is cheap, 
minimally invasive and widely available in clinical settings. It is a very good screening 
method in demonstration of supratentorial abnormalities but MRI is additional sequences 
which are mandatory for better anatomical distinction when it comes to decision of surgical 
interventions.  
There are various structural features which are of interest to radiologist in answering the 
critical question in tumour assessment: 
i. Signal contrast with respect to normal brain parenchyma 
ii. Tumour structure, margins, extent of perifocal edema 
iii. Indirect tumour signs (compression syndrome, midline shift etc.) 
iv. Tumour vascularity, main vessels supplying the tumour and its course 
v. Degree of contrast enhancement 
The information provided by MRI in evaluating brain lesions is critical for accurate 
diagnosis, therapeutic intervention and prognosis. Contrast-enhanced MR neuro-imaging 
using gadolinium (Gd) contrast agents depicts blood-brain barrier disruption, thereby 
demonstrating the location and extent of the tumour by depicting the increased 
extracellular-extravascular space (EES) contrast concentration in these areas.  
However, simple contrast-enhanced morphologic imaging is limited in accurately predicting 
tumour aggressiveness. Adding dynamic contrast-enhanced and perfusion-weighted 
imaging can solve this problem by providing physiological information – such as 
haemodynamic and neo-angiogenic status – in addition to pure lesion morphology. T1-w 
and T2* perfusion imaging in a follow-up scan can differentiate treatment success by 
differentiating between radiation necrosis and tumour recurrence. 
Most available Gd-contrast agents have similar T1 and T2 relaxivities, and thus comparable 
tissue-enhancing properties. The exceptions are gadobenate, gadoxetate and gadofosveset, 
all of which have transient protein-binding capability that is responsible for up to twice (and 
more) the R1 and R2 relaxivity as compared to the other agents at all magnetic field 
strengths [2].  
Table 1 summarizes the indication, advantages and limitation of CT and MRI before we 
move on to each modality in details. 
3. Magnetic resonance imaging studies in brain tumour 
MR imaging is an important diagnostic tool in the evaluation of intracranial tumours. Its 
effectiveness is due to its inherent high sensitivity to pathologic alterations of normal 
parenchymal water content, as demonstrated by abnormal high or low signal intensity on 
T2- or T1-weighted images, respectively. Compared to CT, MR imaging allows more 
accurate determination of lesion location, extent and better demonstrates subtle mass effects 
or atrophy, particularly along the cerebral convexities. MR imaging better depicts the 
presence of subacute or chronic haemorrhage and permits more accurate distinction 
between a vascular structure and adjacent parenchyma. CT is superior in depicting the 
presence of calcification and bone abnormalities, e.g. destruction, erosion, permeation, and 
hyperostosis. MR imaging is superior to CT for differentiating between tumour and 
perifocal edema, for defining extent of tumour, and for showing the relationship of the 
tumour to critical adjacent structures. Heavily T2-weighted sequences are the most sensitive 
for the detection of tumour and edema extent (discussed later in the chapter), but the 
tumour focus is not well separated from surrounding edema. T1-weighted images following 
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contrast enhancement generally provide better localization of the tumour nidus and 
improved diagnostic information relating to tumour grade, blood-brain barrier breakdown, 
haemorrhage, edema and necrosis. Contrast-enhanced T1-weighted images also better show 
small focal lesions such as metastases, small areas of tumour recurrence, and ependymal or 
leptomengeal tumour spread because of improved signal contrast. Proton density images 
are useful for distinguishing tumour and edema from adjacent cerebrospinal fluid, which 
may have a similar appearance as high-signal areas on heavily T2-weighted images. All this 
information is essential for surgical planning. 
 
Modality Indications Limitations
Computed 
Tomography 
1. Shorter imaging time 
2. Low cost of scanning 
3. Better spatial resolution 
4. Good for extra-axial brain tumour 
assessment 
5. Superior in detection of calcifications, 
skull erosion, penetration, destruction 
1. Poor definition of edema 
2. Only one plane 
acquisition and most of 
the time non-isotropic 
3. X-ray radiation risk 
4. Poor tissue 
characterization 
5. Imaging of posterior 
fossa is limited due to 
bone artifacts 
Magnetic 
Resonance 
Imaging 
1. Good in demonstration of edema of 
parenchyma (early sign for tumour 
detection) 
2. Accurate delectating extent of edema 
and compression effects 
3. Better detection of mass effects and 
atrophy 
4. High neuroanatomical definition (tissue
differentiation) 
5. Accurate detection of vascularity of 
tumour (in various planes acquisition) 
1. Poor detection of 
calcification and bone 
erosions 
2. Not possible in 
intraoperative 
assessment 
3. Lower spatial fidelity  
4. Sometime sequence are 
very time consuming 
Table 1. Comparison of CT and MRI in assessment of Brain Tumours 
As indicated in various studies, imaging findings in MR studies roughly correlate with the 
histologic grading of cerebral gliomas. Generally, masses that are sharply marginated, are 
homogeneous in signal intensity, and show little or no contrast enhancement tend to be low-
grade gliomas. Masses that have indistinct margins, are inhomogeneous in appearance, and 
demonstrate intense, irregular contrast enhancement tend to be high-grade gliomas. These 
are generalizations and all of the imaging findings and contrast-enhancing patterns must be 
considered together. Additionally, individual cases may differ from the norm. Some low-
grade astrocytomas that are primarily infiltrating and histologically benign demonstrate 
poor margination with the surrounding brain and some rapidly growing malignant gliomas 
may show sharp margination from the surrounding brain. 
Dean et al. (1990) found the degree of mass effect and the presence of cyst formation or 
necrosis to be statistically significant positive predictors of tumour grade. Central 
nonenhancing zones within an enhanced mass suggest areas of necrosis and indicate rapid 
tumour growth that outstrips the blood supply. This is a manifestation of malignant 
www.intechopen.com
 Diagnostic Techniques and Surgical Management of Brain Tumors 
 
30
behaviour and should suggest the diagnosis of glioblastoma multiforme. Similarly, areas of 
hemorrhage within a mass also favour a malignant lesion and are most often seen with 
glioblastomas or metastases. 
Very large zones of edema surrounding an enhancing intra-axial tumour also favour the 
diagnosis of a malignant lesion and contribute to the mass effect associated with these 
tumours. A notable exception to this rule is meningioma, which, although a benign tumour, 
is often associated with large areas of adjacent edema and mass effect. However, these 
tumours are readily distinguished from malignant gliomas by their extra-axial location. 
Low-grade gliomas tend to exhibit an infiltrating pattern resembling edema on 
neuroimaging studies, but the lack of contrast enhancement and the absence of large mass 
effects that generally accompanies large zones of cerebral edema help to distinguish these 
entities. 
Calcification within a tumour usually indicates a slowly growing neoplasm. Calcification can 
frequently be demonstrated in classic oligodendrogliomas and gangliogliomas and may 
occasionally be seen in astrocytomas and ependymomas. 
Limitations to the usefulness of MR imaging to date are the following: 
1. It does not provide a precise histologic diagnosis because of considerable overlap 
between the characteristic morphologic changes associated with various intracranial 
lesions necessitating surgical biopsy in virtually all cases prior to definitive therapy. 
2. MR images represent computer-generated maps of a spatial representation of 
differences in water proton T1 and T2 relaxation characteristics. Although significant 
pathologic abnormalities usually alter these characteristics, in some instances they may 
not change detectably from normal. If, as may occur with small tumours or with 
infiltrative gliomas, there is no significant mass effect distorting normal anatomy, the 
lesion may go undetected. 
3. Even when there is a well-defined enhancing tumour nidus, infiltrating tumour and 
isolated tumour cells can extend several centimetres beyond the enhancing region into 
the surrounding ‘edematous’ zone and, in some cases, beyond any abnormality seen on 
the image. 
4. Bulk calcium emits no MR signal, making tumour calcification difficult or impossible to 
detect unless present in large amounts. 
5. Artefacts can degrade image quality to nondiagnostic levels. Patient motion during 
image acquisition may introduce abnormal ‘bright’ or ‘dark’ areas in a normal brain 
that can even simulate a lesion. 
6. Magnetic field inhomogeneity presents problems with spatial resolution. 
4. Brain tumour imaging using gadolinium contrast agents 
The most common clinical application of CE-MR neuroimaging is in the evaluation of 
primary and secondary brain tumours. The goals of conventional brain tumour imaging are 
the sensitive detection and delineation of tumour to make a correct diagnosis and accurate 
tumour grading to facilitate appropriate intervention.  
In addition, CE-MR helps localize adjacent critical structures such as vessel or nerves to aid 
surgical or radiotherapeutic planning. MRIs of brain lesions also play a vital role in post-
interventional monitoring by determining response to treatment – and hence prognosis – as 
early identification of treatment failure can help to select an alternative therapeutic 
approach, thus potentially improving patient outcomes.  
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The protocol followed by most of the clinicians includes a T1w, T2w and also T1 post-
contrast image acquisition of the brain tumour prior to present perfusion maps. T1 and T2 
images give a good anatomical image quality and contrast with well-demarcated tumour 
boundaries. We also need T1-w for selecting good region of interest (ROI) of the tumour for 
relevant perfusion map (Figure 1). Dynamic Susceptibility Contrast (DSC) MRI can provide 
information on tumour vascularity which might not be obvious by T1/T2 imaging only but 
will be potential in grading the tumour and management options [3]. 
A standard dose of gadolinium contrast agent is considered to be 0.1mmol/kg bodyweight, 
although many studies have been published demonstrating improved diagnostic 
performance with double (0.2mmol/kg) or even triple (0.3mmol/kg) doses,[4;5] and this has 
become routine clinical practice.  
Although higher doses of contrast agent have potentially increased the cost of MR 
examinations and are associated with higher false-positive rates,[5;6] such doses are very 
sensitive when determining the extent of the disease is the primary goal. The high molarity 
1% Gd contrast gadobutrol (Gadovist) is also shown to be very sensitive (Figure 1) in 
detecting tumour activity [7]. Essig et al. compared 0.1 and 0.2 mmol/kg body weight doses 
of 1 M gadobutrol and gadobenate dimeglumine at 1.5 T in healthy volunteers and found 
that although the peak signal fall with the double dose of both agents was larger, there were 
no statistical differences between agents or doses (Fig. 5) [8]. Moreover, a signal drop of 
approximately 40% was produced by single doses of both agents, sufficient to permit 
calculation of highquality CBV and CBF maps. In this case, bolus widths achieved with 
gadobenate dimeglumine and gadobutrol were sharp and comparable, and therefore, the 
reduced injection time of gadobutrol did not have a positive effect on the bolus geometry. 
Essig and colleagues concluded that at 1.5 T, both the 1 M gadobutrol and the higher 
relaxivity gadobenate dimeglumine permitted a sufficient drop in SI to afford robust and 
reproducible quantification of haemodynamic parameters and that the slightly lower 
volume of the injection of gadobutrol did not produce any major advantage in terms of 
bolus geometry  [8]. 
Improving the diagnostic performance by using a higher relaxivity contrast agent is an 
equally good alternative to increasing gadolinium dose. Early dosing studies demonstrated 
that double doses of gadobenate dimeglumine are potentially beneficial, with enhanced 
sensitivity in brain tumour detection, although no further benefit is seen when increasing to 
triple dose [9;10]. 
The more significant evidence of improved diagnostic performance by the higher relaxivity 
agent, however, came from a series of intra-individual crossover studies directly comparing 
gadobenate dimeglumine with gadopentetate dimeglumine,[11-16] gadoterate meglumine 
[11;13], gadodiamide[11;17] and gadofosveset trisodium. In these crossover studies, patients 
underwent two otherwise identical MR examinations, one with each contrast agent, within a 
gap of two days to two weeks, thus enabling any differences between the two imaging sets 
to be directly attributed to the contrast agents being used (Figure 2-5) [2;12-14].   
The first such crossover study, performed in 2001, demonstrated that in patients with 
metastatic central nervous system (CNS) disease, the sensitivity for lesion detection with 
gadobenate dimeglumine (93%-100%) was much higher than that with an equal dose of 
comparator (65%-73%), like gadopentetate dimeglumine (N=13), gadodiamide (N=4), or 
gadoterate meglumine (N=5)[11]. In addition, tissue contrast in the main lesion-to-normal 
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brain parenchyma was consistently greater for gadobenate dimeglumine (143%) than for an 
equal dose comparator (127%) as compared to unenhanced images.  
 
 
Fig. 1. a) T1-weighted; b) T2-weighted; c) T1-w post Gd-DTPA contrast; d) T1-w post 
Gadobutrol contrast; e) T2* weighted parametric CBV map with Gd-DTPA; f) T2* weighted 
parametric CBV map with Gadobutrol. Gadobutrol is shown to be more sensitive and show 
more number of active lesions in tumour with high blood supply.[4]. 
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Fig. 2. Matched pairs of T1-weighted spin echo images from intraindividual comparative 
studies with high relaxivity enhanced images shown on the left and the comparator-enhanced 
image on the right. Where present, arrows highlight additional information present on 
gadobenate-dimeglumine-enhanced images. From Colosimo et al. [13] presenting a patient 
with malignant glioma (arrow head) gadobenate dimeglumine-enhanced MRI, which allows 
beside the stronger enhancement, the depiction of a satellite lesion (arrow) not present on the 
comparator image. The satellite-enhancing lesion should be integrated into the target volume 
for therapeutic intervention. 
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Fig. 3. A patient with multiple cerebral metastases, gadobenate dimeglumine-enhanced MRI 
is able to show additional metastases in the left cerebellar hemisphere (left) and a larger 
appearance of the lesion in projection of the midline (from Knopp et al. [12]). High relaxivity 
enhanced images shown on the left and the comparator-enhanced image on the right. 
 
 
Fig. 4. A patient with multiple metastases, a high relaxivity agent allowed the detection of 
additional lesions and the proved the infiltration of the meninges (from Maravilla et al. [14]). 
High relaxivity enhanced images shown on the left and the comparator-enhanced image on 
the right. 
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Fig. 5. The patient with an infiltration of the menigiosis carcinomatosa and a focal metastatic 
lesion, the enhancement is more pronounced with the use of a high relaxivity agent, and the 
lesion appears to be substantially larger (from Essig et al.[2]). High relaxivity enhanced 
images shown on the left and the comparator-enhanced image on the right. 
Since then, five larger, prospective, randomised, intra-individual crossover studies have 
been performed with a total of 355 patients in which gadobenate dimeglumine was directly 
compared with an equal dose of other non-protein-binding contrast agents for MRI of 
primary and secondary CNS lesions[12-14;16;17].  
Qualitatively blinded readers expressed global preference for images enhanced with 
gadobenate dimeglumine versus the other standard agents. Additionally, an independent 
analysis of intra-axial enhancing brain lesions (N=158) demonstrated a highly significant 
(p≤0.0156, all readers) improvement with gadobenate dimeglumine compared to 
gadopentetate dimeglumine, both qualitative and quantitatively[15].  
All of the above-mentioned comparison studies between various MR contrast agents were 
performed using the field strength of 1.5T or less, while the recent crossover study by 
Rumboldt et al was performed using a 3T magnet[16]. The study demonstrated the 
persistent benefits of high-relaxivity agents even at higher field strengths, which will be the 
focus of clinical research in coming years. 
An additional consideration recently is the fear of nephrogenic systemic fibrosis (NSF) 
developing in certain patient populations when higher doses of Gadolinium are used [18-
20], NSF and other side-effects of MR contrast agents are beyond the remit of this chapter, 
but are worth mentioning here. 
5. T1 weighted MR imaging in brain tumours 
T1 weighted (T1w) MRI needs a special mention in brain tumour evaluation, because on 
many occasions the blood-brain barrier (BBB) is damaged in tumours, which alters the 
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normal one-compartment physiological model used in imaging for perfusion analysis. The 
T1-w enhancement of contrast agent is attributed to BBB leakage associated with 
angiogenesis and capillary damage in regions of active tumour growth.  
Angiogenesis is an important contributor to tumour growth and correlates with tumour 
aggressiveness. As angiogenesis increases microvascular cerebral blood volume (CBV), 
CBV-imaging may provide a unique insight into tumour physiology, histology and response 
to therapeutic agents. Different imaging modalities such as PET and MRI-CBV methods 
have been employed in tumour imaging for some time, but both require appropriately 
timed injection of contrast agents and subsequent post-processing, making them logistically 
difficult.  
Recently, a new MRI approach called vascular-space-occupancy (VASO) imaging was 
developed as a non-invasive method for detecting CBV changes accompanying neuronal 
activation. VASO is a T1-weighted MRI approach that exploits the T1 difference between 
blood and tissue to null intravascular blood signal, simultaneously giving an image of 
extravascular tissue water, but only as it relates to parenchyma tumour.  
While VASO has shown consistent sensitivity to CBV changes in functional MRI, it has not 
been tested extensively in the clinical setting for tumour imaging. Recently, VASO images 
with and without contrasts were combined to quantitatively assess absolute CBV in brain 
tumours, showing promise for assessing tumour grade assessment. However, this approach 
is confounded by the assumption that the administered contrast remains in the vasculature 
(single-compartment perfusion model), which may not be applicable in regions of BBB 
breakdown (two-compartment perfusion model).  
The studies have also demonstrated that VASO and MPRAGE (magnetisation prepared 
rapid gradient echo) MRI provide contrast complementary to Gd-T1w and FLAIR (fluid 
attenuation inversion recovery) MRI for tumour imaging. Interestingly, FLAIR, VASO and 
MPRAGE are all inversion-based MRI sequences. However, they each offer a range of T1w 
contrasts, of which a collective analysis provides information not otherwise evident[21]. 
6. MR Spectroscopy (MRS) in tumour grading 
Clinical applications of magnetic resonance spectroscopy (1H-MRS) are increasing as the 
techniques with (techniques and hardware have become more robust with fast processing) 
hardware have become more robust and fast processing. Proton MRS provides biochemical 
and metabolic information about tumours and normal brain [22]. The information obtained 
from MRS for tumour is unique and complimentary to other MR Imaging techniques. 
As with other organs spectroscopy of brain tumours can be done in single- or multi- voxel 
forms. The two most widely used methods for volume selection are stimulated echo 
acquisition mode (STEAM) and point-resolved spectroscopy sequence (PRESS). In general 
STEAM is better as shorter echo times can be achieved with it but, it is more sensitive to 
motion related artefacts [23]. In theory, for the same total echo time, the signal of PRESS is 
twice as great as that of STEAM; also PRESS is also less sensitive to motion. With faster and 
better softwares PRESS is getting more commonly used method of volume selection in 
clinical practice. 
Single voxel MRS is sometimes better as it’s faster and quick to acquire but it lacks the high 
spatial resolution and hence regional mapping of metabolic variations. Brain tumours are 
heterogeneous in their tumours potentials; therefore single voxel spectroscopy might not be 
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very reliable in tumour grading based on its metabolic activity. Poor spatial resolution also 
makes it vulnerable to high partial volume artefacts.  
In the spectroscopy the most commonly used echo times are 144 msec and 270 msec at 
which the spectrum is dominated by 5 different metabolite peaks. These are the choline 
(Cho), creatine (Cr), N-acetylaspartate (NAA), lactate, and lipid. The choline peak reflects 
cell membrane turnover; Creatine is a good marker for energy synthesis, and NAA is 
exclusive to neuronal cells. Lactate resulting from anaerobic metabolism (which is 
uncommon in normal brain parenchyma) is detected in necrotic/infarcted tumour [24]. 
Cellular and myelin breakdown products result in prominent lipid peaks in MRS. MR 
Spectroscopy allows analysis of these specific metabolites within brain tissue. Tumours, 
especially primary brain tumours show very specific pattern in elevation of choline and loss 
of N-Acetyl Aspartate peaks [25;26].  
Combined with MRI, MRS can aid in the evaluation of tumour type and grade. The higher-
grade gliomas tend to exhibit higher Cho/Cr and Cho/NAA ratios. MR spectroscopy can 
help differentiate enhancing tumour from other causes of enhancement (mainly necrosis) 
and is more specific in differentiating nonenhancing tumour from edema and other causes 
of T2 prolongation. These qualities have been exploited in order to better define the true 
extent and morphology of gliomas. This information has the potential to significantly alter 
target volumes and radiation therapy doses of brain gliomas when compared with 
conventional radiotherapy. Although this is an attractive concept, there are no studies to 
show benefits, changes in failure patterns, or improved survival. MR spectroscopy is 
utilized more and more by different groups in assessing response to therapy in patients with 
primary brain tumours or metastases. MR spectroscopy can noninvasively enable the 
distinction between a solitary metastasis and high-grade gliomas, particularly when 
combined with perfusion MR imaging [27]. In their study, Law et al showed that 
measurements of Cho and mean rCBV in the perienhancing region are useful in 
differentiating solitary metastases from high-grade gliomas. In the perienhancing region, T2 
prolongation is partly due to tumour infiltration (nonenhancing tumour) in patients with 
high-grade gliomas. Whereas in the case of metastases, the hyperintensity surrounding the 
region of enhancement is due to vasogenic edema or nonspecific treatment effects rather 
than infiltrating tumour. Therefore, elevated levels of choline and/ or rCBV surrounding a 
peripherally enhancing mass reflect tumour infiltration in a high-grade glioma.  
Post- treatment, MRS has a much limited role in the assessment of patients. Frequently, 
there is a mixture of ruminant tumour and necrosis after therapy. This limits the utility of 
MRS in differentiating residual/recurrent tumour from radiation necrosis, as is the case 
with MR perfusion. As a tumour responds to treatment, the choline decreases and lactate 
and/or lipids may increase [28;29]. MR spectroscopy can play a useful role after treatment 
in assessing the therapeutic response. This is particularly important for early detection of 
treatment failure so that an ineffective treatment can be modified prior to a significant 
progression of disease. 
7. Molecular imaging and PET in brain tumour imaging 
PET imaging is a non-invasive diagnostic imaging tool that has an advantage over 
anatomical imaging in that it is a metabolic imaging tool that is able to distinguish between 
benign and malignant tumours. It is often used to accurately determine the stage of the 
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brain tumour. PET images produce visual impression of detailed biochemical changes 
caused by brain tumours and their metabolic activities.  
Despite the recognized limitations of fluorodeoxyglucose positron emission tomography 
(FDG-PET) in brain tumour imaging due to the high background of normal gray matter, this 
imaging modality provides critical information for the management of patients with 
cerebral parenchyma tumours by providing a: 
 Global picture of the tumour and thus guiding the appropriate site for biopsy, thereby 
improving accuracy of the technique and reducing the number of biopsy samples  
 Prediction of metabolic activity and aggressiveness of the tumour, thereby enhancing 
the ability to provide a prognosis.  
Another area, which has been investigated extensively in tumour imaging, is differentiating 
between recurrent tumour and treatment-related changes – for example, radiation necrosis 
or postsurgical changes. The aggressive tumour responds with a bright signal because of its 
high uptake of FDG, but radiation necrosis will show no changes.  
FDG-PET has equally demonstrated its usefulness in differentiating lymphoma from 
infectious toxoplasmosis in patients with acquired immune deficiency syndrome with 
almost 100% accuracy, and is the investigation of choice in that setting [30].  
In recent years, an increasing number of brain tumour PET studies have used other tracers, 
such as labeled methionine, tyrosine, thymidine, choline, fluoromisonidazole, EF5 and so 
on, of which positron-labeled amino acid analogues, nucleotide analogues, and the hypoxia 
imaging tracers are of special interest [30]. The major advantage of these radiotracers over 
FDG is the markedly reduced background activity in gray matter, which allows detection of 
even smaller lesions and low-grade tumours with high precision.  
The promise of the amino acid PET (Figure 6) tracers has been emphasized due to their 
higher sensitivity in imaging recurrent tumours (particularly the low-grade) and better 
accuracy for differentiating between recurrent tumours and treatment-related changes 
compared with FDG. O-(2-[18F]fluoroethyl)-L-tyrosine (FET) is a potential new amino acid 
PET tracer that has been shown to be helpful as an additional tool in few patients by 
allowing better differentiation of tumour tissue from inflammatory tissue. Another possible 
application of 18F-FET PET being considered is in the monitoring of radio- or chemo-
therapy of squamous cell carcinoma (SCC), because the reaction of the tumour tissue may be 
specifically detected without the interfering the uptake by inflammatory or reactive tissue 
[31].  
The newer PET tracers have also shown great potential to image important aspects of 
tumour activity and thereby demonstrate ability in predicting right prognosis response. The 
value of hypoxia imaging tracers (such as fluoromisonidazole or more recently EF5) is 
substantial in radiotherapy planning and predicting treatment response. In addition, they 
may play an important role in the future in directing and monitoring targeted hypoxic 
therapy for tumours with hypoxia.  
8. Future trends 
With the further technological advancements in imaging modalities and contract agents the 
brain tumour imaging is getting benefited. The high relaxivity contrast agents are able to 
provide vital information on tumour vascularity and higher magnetic strength scanner 
having higher SNR are getting more focus for clinical usage. The PET-MR is no more a 
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research prototype but is getting validated with clinical trials which will be available for 
clinics very soon. Even the newly available CT technology, Multi-Energy Computed 
Tomography, which operates on material characterization properties by multi-energy 
(commonly two) CT acquisition is the promising technology for anatomical and tumour 
functional information accessed at the same time [32]. 
 
 
 
 
 
 
 
Fig. 6. Patient with a recurrent locoregional brain lesion – images show tumour before and 
after neurosurgery and radio-chemotherapy. a, d) FET-PET image showing intense uptake 
in the tumour tissue before and recurrent tumour after neurosurgery; b, e) Fused PET-CT 
image confirming the location of the tumour and recurrent lesion before and after surgery; c, 
f) post contrast MRI image in concordance to strong FET-tracer uptake  shown in PET/CT. 
Furthermore, an additional brain lesion was identified in the right parietal lobe medial area 
of the brain tissue resected area, presenting a high FET-tracer uptake in PET/CT and strong 
contrast enhancement in MRI.   
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9. Conclusion 
Brain tumour imaging consists of anatomical imaging with CT and perfusion MRI and 
functional imaging with PET. Physicians need both anatomical and functional imaging 
information to be assessed at the same time for appropriate treatment planning. The future 
of tumour imaging lies in developing optimal image registration and segmentation 
strategies from multimodality imaging as well as novel PET tracers. This approach is also set 
to play a role in the era of intensity-modulated radiotherapy, and is likely to have important 
clinical and research applications in radiotherapy planning in patients with brain tumours. 
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